# colorectal cancer - deepseek-v4-flash

- Benchmark system: raw
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: disabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: DeepSeek / deepseek-v4-flash
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 3704
- Completion tokens: 17571
- Reasoning tokens: 
- Total tokens: 21275
- API requests reported: 
- Elapsed seconds: 188.416
- Final benchmark system: raw; file rank 4/5; original repeat 6; model vendor: DeepSeek

---
## Important caveat before interpretation

The input is a prognostic association table from bulk colorectal tumor tissue: each gene has a unadjusted or minimally reported hazard ratio (HR), \(P\) value, and FDR for overall survival. HR > 1 means higher expression is associated with worse OS; HR < 1 means higher expression is associated with better OS. The table does not provide adjustment for stage, treatment, microsatellite status, tumor purity, or cell composition. Therefore, the interpretations below are hypothesis-generating survival associations, not causal or cell-type-resolved conclusions.

---

# 1. Overall biological interpretation

The overall survival-associated transcriptome in this colorectal cancer dataset points to a coherent biological axis:

- **Worse survival is associated with a mesenchymal / EMT-like and stromal-remodeling phenotype**, involving TGFβ/activin signaling, actin-microtubule remodeling, extracellular matrix/interaction genes, and some metabolic and growth-factor risk signals.
- **Better survival is associated with retained intestinal epithelial differentiation and mitochondrial oxidative metabolism**, including enterocyte lineage transcription factors such as CDX1/CDX2, brush-border/intestinal markers such as LGALS4 and MYO5B, and multiple nuclear-encoded mitochondrial respiratory or metabolic genes.

In colorectal cancer, this pattern is biologically recognizable. Poor-prognosis tumors frequently lose intestinal differentiation, activate epithelial–mesenchymal transition (EMT), acquire a more mesenchymal/stromal transcriptome, and shift toward glycolytic metabolism. Favorable-prognosis tumors more often retain CDX2-dependent enterocyte identity and oxidative mitochondrial metabolism. The data therefore likely reflect a combination of tumor-cell-intrinsic differentiation state and microenvironmental/stromal content rather than a simple single-gene effect.

---

# 2. Core biological programs

## Program 1: TGFβ/activin-driven EMT and stromal/matrix remodeling

**Prognostic direction:** Risk-associated (HR > 1)

**Major supporting genes:**  
INHBB, ZEB1-AS1, DCBLD2, TPM4, ABL2, MAP1B, NIN, BICD1, ITGBL1, ADAMTS18, LRRC4C, NT5E, MSLN, PTPN14, SCARA3, GJB6, SCEL

**Best-matched pathway:**  
Hallmark “Epithelial Mesenchymal Transition”; Reactome “Extracellular matrix organization” and “Signaling by TGFB family members”; KEGG “TGF-beta signaling pathway”

**Interpretation:**  
INHBB encodes an activin/inhibin βB subunit and is one of the strongest risk signals in the dataset. It belongs to the TGFβ superfamily, which can drive EMT and mesenchymal invasion in colorectal cancer. ZEB1-AS1 is an antisense lncRNA at the ZEB1 locus; ZEB1 is a master EMT transcription factor. DCBLD2, TPM4, ABL2, MAP1B, NIN, BICD1, LRCH3, and LRCH1 are cytoskeleton-, microtubule-, or centrosome-related genes that could act as downstream effectors of cytoskeletal remodeling during invasion. ITGBL1, ADAMTS18, MSLN, and NT5E support ECM interaction, matrix degradation, or tumor–microenvironment communication. The co-occurrence of TGFβ-superfamily, EMT-regulatory, cytoskeletal, and ECM-remodeling genes strongly suggests that this is not a random set of individual genes but a coordinated biological program.

**Strength and limitation:**  
This is one of the most coherent signals in the dataset and is supported by multiple independent gene families. The main limitation is that bulk tumor tissue may contain cancer-associated fibroblasts and other stromal cells; some of these “EMT” signals could reflect stromal content rather than tumor-cell EMT.

---

## Program 2: Intestinal epithelial differentiation and enterocyte identity

**Prognostic direction:** Protective (HR < 1)

**Major supporting genes:**  
CDX1, CDX2, LGALS4, MYO5B, MYB, PRR15L, DNPEP, DBI

**Best-matched pathway:**  
Gene Ontology biological process “intestinal epithelial cell differentiation”; functionally linked to enterocyte lineage programs

**Interpretation:**  
CDX1 and CDX2 are master transcription factors for intestinal identity. Higher expression of these genes is associated with better survival, consistent with the well-known observation that CDX2 loss in colorectal cancer defines a more aggressive, poorly differentiated subtype. LGALS4 encodes galectin-4, a marker of differentiated enterocytes. MYO5B is required for enterocyte apical vesicle trafficking and brush-border function. MYB is a transcription factor with complex roles in intestinal biology; in this dataset its expression is protective, which may reflect a differentiation/intestinal-proliferation context rather than its oncogenic roles in other tumor types. This program is essentially the opposite of the EMT/mesenchymal program: tumors that maintain intestinal epithelial identity have a better prognosis.

**Strength and limitation:**  
The signal is supported by canonical colorectal cancer biology and multiple enterocyte-specific genes. However, part of this association may reflect tumor purity or grade: differentiated tumors contain more epithelial cell content and fewer stromal cells, so the protective effect may be partly a proxy for histological differentiation or CMS subtype.

---

## Program 3: Mitochondrial oxidative metabolism and catabolic energy metabolism

**Prognostic direction:** Protective (HR < 1)

**Major supporting genes:**  
NDUFA9, ATP5B, ATP5G1, ATP23, COA3, TIMM13, CS, OGDHL, MCCC2, ACSS2, PRELID2, GLYCTK, ILVBL, ASL, PXMP2, DBI

**Best-matched pathway:**  
KEGG “Oxidative phosphorylation”; Hallmark “Oxidative Phosphorylation”; Reactome “The citric acid (TCA) cycle and respiratory electron transport”; KEGG “Valine, leucine and isoleucine degradation” partially

**Interpretation:**  
Multiple nuclear-encoded mitochondrial genes are protective: NDUFA9 is a complex I subunit; ATP5B and ATP5G1 are ATP synthase subunits; ATP23 and COA3 are mitochondrial assembly/oxidative phosphorylation factors; TIMM13 is a mitochondrial import protein; CS and OGDHL are TCA cycle enzymes; MCCC2 is a mitochondrial leucine catabolism enzyme; ACSS2 feeds acetyl-CoA into metabolism; PXMP2 is peroxisomal membrane protein. The coordinated protective direction suggests that tumors with preserved mitochondrial oxidative metabolism and catabolic efficiency have better overall survival, whereas more aggressive tumors may rely on glycolysis and biosynthetic reprogramming.

**Strength and limitation:**  
This is a large, cross-gene, pathway-coherent signal. But it is not direct metabolic evidence: mRNA levels do not prove oxidative phosphorylation activity, and the signal could partly reflect differentiation status or mitochondrial content rather than a specific tumor metabolic dependency.

---

## Program 4: Glucose uptake / glycolytic and growth-factor-associated metabolic reprogramming

**Prognostic direction:** Risk-associated (HR > 1)

**Major supporting genes:**  
SLC2A3, AKT3, FGF19, GADD45B, CYP1B1, BACE1, SCARA3

**Best-matched pathway:**  
Hallmark “Glycolysis”; KEGG “PI3K-Akt signaling pathway”; Reactome “Glucose transport”

**Interpretation:**  
SLC2A3 encodes GLUT3, a high-affinity glucose transporter, and its higher expression is associated with worse survival. AKT3 is a PI3K/AKT isoform that can promote cell survival and metabolic reprogramming. FGF19 is a fibroblast growth factor with oncogenic activity in digestive cancers, and FGF signaling can feed into PI3K/AKT and metabolic pathways. GADD45B is a stress-response gene that can support survival under oncogenic stress. CYP1B1 is a xenobiotic-metabolizing enzyme associated with aggressive tumor behavior in some contexts. The combination of glucose-transport, growth-factor, and stress-response genes suggests a risk-associated shift toward glucose-dependent metabolism and pro-survival signaling, which is biologically complementary to the protective mitochondrial metabolic program.

**Strength and limitation:**  
This program is less strongly supported than the first three because the number of clearly “glycolytic” genes is small; SLC2A3 is the most direct metabolic gene. AKT3 and FGF19 could also belong to a separate growth-factor program, but their inclusion here is justified by their role in metabolic and oncogenic signaling. The evidence is more limited and should be treated as suggestive.

---

# 3. Key genes and interaction modules

### 1. INHBB
- **Dataset direction:** Risk: HR 1.43, FDR 0.001; strongest risk signal.
- **Potential role:** TGFβ-superfamily ligand; likely upstream of EMT and stroma activation.
- **Proposed relationship:** Pathway co-membership with TGFβ/SMAD signaling; possibly indirect regulatory influence on ZEB1/EMT genes, but no direct interaction is proven by these data.

### 2. ZEB1-AS1 / ZEB1 axis
- **Dataset direction:** Risk: HR 1.37, FDR 0.009.
- **Potential role:** Antisense lncRNA at the ZEB1 locus; ZEB1 is a master EMT transcription factor.
- **Proposed relationship:** Regulatory interaction, because ZEB1-AS1 is genomically antisense to ZEB1 and has been reported to regulate ZEB1 expression in other cancers. This is not direct physical protein interaction and needs CRC-specific validation.

### 3. DCBLD2
- **Dataset direction:** Risk: HR 1.41, FDR 0.009.
- **Potential role:** Transmembrane protein implicated in invasion, proliferation, and EMT-like phenotypes.
- **Proposed relationship:** Likely downstream effector or co-expressed partner of EMT/cytoskeletal programs; direct molecular partner unknown.

### 4. NT5E / CD73
- **Dataset direction:** Risk: HR 1.31, FDR 0.039.
- **Potential role:** Ecto-5′-nucleotidase generating adenosine; promotes immunosuppressive tumor microenvironment and can support invasion.
- **Proposed relationship:** Indirect microenvironmental relationship rather than direct intracellular interaction with the other risk genes.

### 5. SLC2A3 / GLUT3
- **Dataset direction:** Risk: HR 1.28, FDR 0.072; suggestive.
- **Potential role:** High-affinity glucose transporter; supports glycolytic metabolism.
- **Proposed relationship:** Pathway co-membership with glucose metabolism; functionally opposite to the protective mitochondrial oxidative phosphorylation program.

### 6. CDX1 / CDX2 enterocyte module
- **Dataset direction:** Protective: CDX2 HR 0.75, FDR 0.035; CDX1 HR 0.78, FDR 0.057; LGALS4 HR 0.77, FDR 0.051; MYO5B HR 0.75, FDR 0.028.
- **Potential role:** Intestinal lineage identity and differentiation; low expression may indicate aggressive, undifferentiated CRC.
- **Proposed relationship:** CDX1 and CDX2 are co-expressed intestinal transcription factors and share regulatory targets; this is a regulatory/transcriptional network relationship, not a direct physical interaction.

### 7. Mitochondrial oxidative phosphorylation protective module
- **Dataset direction:** Protective: NDUFA9, ATP5B, ATP5G1, CS, COA3, TIMM13, OGDHL, MCCC2, etc.
- **Potential role:** Preservation of mitochondrial oxidative metabolism; likely tied to differentiation and less aggressive tumor behavior.
- **Proposed relationship:** Some genes are physically part of respiratory complexes by annotation, e.g., NDUFA9 in complex I and ATP5B/ATP5G1 in complex V; COA3 and TIMM13 support assembly/import. This is pathway/protein-annotation evidence, not evidence from the survival dataset itself.

### 8. ABL2
- **Dataset direction:** Risk: HR 1.30, FDR 0.028.
- **Potential role:** Non-receptor tyrosine kinase involved in actin cytoskeleton dynamics, cell migration, and invasion.
- **Proposed relationship:** Pathway co-membership with actin/microtubule remodeling; may overlap functionally with TPM4, MAP1B, and DCBLD2, but direct interactions are not established here.

### 9. FGF19 / AKT3 growth-factor module
- **Dataset direction:** Risk: FGF19 HR 1.29, FDR 0.051; AKT3 HR 1.32, FDR 0.039.
- **Potential role:** Pro-oncogenic growth-factor signaling; FGF19 can signal through FGFRs and downstream PI3K/AKT; AKT3 is an AKT isoform controlling survival and metabolism.
- **Proposed relationship:** Pathway co-membership in FGF→FGFR→PI3K/AKT signaling; possibly functionally synergistic, but no direct physical interaction is shown.

### 10. MIR31HG
- **Dataset direction:** Risk: HR 1.31, FDR 0.007.
- **Potential role:** Host gene/long non-coding RNA associated with oncogenic phenotypes in several cancers, including colorectal cancer.
- **Proposed relationship:** Putative oncogenic lncRNA; its regulatory targets and relationship to the other risk genes remain unclear.

---

# 4. Validation priorities

### Priority 1: Functional validation of INHBB/activin signaling as a driver of EMT and poor survival
**Classification:** Mechanistic hypothesis  
**Why it deserves prioritization:** INHBB is the strongest risk-associated gene and belongs to the TGFβ superfamily, a central pathway in CRC invasion.  
**Current dataset evidence:** Only survival association: HR 1.43, FDR 0.001.  
**External evidence:** TGFβ/activin signaling promotes EMT in multiple solid tumors; activin receptors and ligands are expressed in CRC stroma and tumor cells.  
**Next step:** Knock down or overexpress INHBB in CRC organoids or cell lines; measure EMT markers, invasion, and metastasis in vivo; test whether activin/SMAD signaling is required.  
**Conclusion:** Supported hypothesis, not established.

---

### Priority 2: CDX1/CDX2 and intestinal differentiation as a prognostic biomarker in independent cohorts
**Classification:** Biomarker  
**Why it deserves prioritization:** CDX2 loss is already a recognized poor-prognosis marker in CRC; this dataset independently shows CDX1, CDX2, LGALS4, and MYO5B as protective.  
**Current dataset evidence:** Protective HRs for CDX2, CDX1, LGALS4, and MYO5B with FDRs near or below 0.05.  
**External evidence:** Multiple studies associate CDX2 loss with poorly differentiated, aggressive CRC; CDX2 has been proposed as a prognostic and subtype marker.  
**Next step:** Validate CDX2/CDX1 protein and mRNA in independent CRC cohorts with stage-adjusted multivariable survival models; test whether the differentiation module adds predictive value beyond CMS subtype or stage.  
**Conclusion:** Supported hypothesis.

---

### Priority 3: Evaluate NT5E/CD73 as a therapeutic target and/or immune-biomarker
**Classification:** Therapeutic target  
**Why it deserves prioritization:** NT5E was risk-associated and is an immunomodulatory target with existing therapeutic agents.  
**Current dataset evidence:** Risk HR 1.31, FDR 0.039.  
**External evidence:** CD73 expression is associated with immunosuppression and poor outcomes in some solid tumors; anti-CD73 antibodies are in clinical development.  
**Next step:** Determine CD73 protein localization on tumor cells versus immune cells in CRC; test CD73 inhibition in CRC-immune co-culture models; evaluate antitumor T-cell responses.  
**Conclusion:** Exploratory hypothesis. The existence of CD73 inhibitors does not itself prove that CD73 is an effective target in colorectal cancer.

---

### Priority 4: Test the ZEB1-AS1 / ZEB1 regulatory axis in CRC EMT
**Classification:** Interaction / network hypothesis  
**Why it deserves prioritization:** ZEB1-AS1 is a risk lncRNA, and ZEB1 is a master EMT transcription factor; this could connect several risk-associated genes.  
**Current dataset evidence:** ZEB1-AS1 is risk-associated in the survival table, but the dataset contains no expression of ZEB1 itself and no direct regulatory evidence.  
**External evidence:** ZEB1-AS1 has been reported to regulate ZEB1 in other cancers, and ZEB1 drives EMT and chemoresistance.  
**Next step:** Measure ZEB1-AS1 and ZEB1 expression in matched CRC samples; perform CRISPR knockdown of ZEB1-AS1 and assess ZEB1 expression, EMT phenotype, and invasion.  
**Conclusion:** Exploratory hypothesis.

---

### Priority 5: Determine whether the stromal/EMT signal is tumor-cell-intrinsic or derived from the tumor microenvironment
**Classification:** Confounding / composition check  
**Why it deserves prioritization:** Bulk tumor tissue contains cancer cells, fibroblasts, endothelial cells, and immune cells. Many risk-associated genes may be expressed predominantly in stromal cells.  
**Current dataset evidence:** The survival associations cannot distinguish cell of origin.  
**External evidence:** CRC CMS4 tumors are enriched for stromal/EMT genes and have worse survival; some genes such as ITGBL1 and INHBB may be stromal/CAF-expressed.  
**Next step:** Use single-cell RNA-seq, spatial transcriptomics, or multiplex IHC to localize INHBB, DCBLD2, NT5E, ZEB1-AS1, and CDX2/OXPHOS markers to specific cell types; adjust survival models for stromal fraction.  
**Conclusion:** Confounding/composition check; currently the EMT/stromal signal should be considered exploratory until cell-type-resolved validation is performed.

---

# 5. Evidence grounding

The interpretations above rest on several different evidence types, and it is important to state their independence and limitations.

- **Direct evidence from the input dataset:** The survival associations themselves. These are statistical associations only and do not provide functional or cell-type information.
- **Pathway/ontology evidence:** The grouping of genes into EMT, intestinal differentiation, oxidative phosphorylation, and glucose metabolism is based on established Gene Ontology, Reactome, KEGG, and Hallmark annotations. This is independent of the survival statistics but is not a direct confirmation that those pathways are mechanistically altered.
- **Protein interaction or regulatory evidence:** Some protective mitochondrial genes are physically part of respiratory complexes by known biochemistry; ZEB1-AS1 is genomically antisense to ZEB1 and has reported regulatory effects. These relationships are from external databases/literature, not from the input table.
- **Disease-association evidence:** CDX2 loss in aggressive CRC, TGFβ/EMT in CRC, CD73 immunosuppression, and GLUT3-related metabolic reprogramming are supported by published clinical and experimental studies. This is partially independent of the current dataset, but literature biases or publication preferences may overrepresent certain genes.
- **Expression/tissue-specific evidence:** CDX1/CXD2, LGALS4, and MYO5B are known intestinal/enterocyte markers; NDUFA9 and ATP5B are broadly expressed mitochondrial components. This helps interpretation but does not prove which cell type drives the survival association.
- **Genetic or clinical evidence:** Not directly available in the input table. Some genes such as CDX2 and FGF19 have prior clinical outcome associations in CRC, but the input dataset does not include genetic alteration data or treatment details.
- **Drug/therapeutic evidence:** Not relevant to interpretation of survival direction; the existence of drugs against NT5E, AKT, FGF19, or ABL2 is not evidence of therapeutic efficacy in CRC.

Where multiple sources support the same conclusion, they are often overlapping. For example, CDX2 is protective in this dataset, is biologically known as an intestinal differentiation factor, and has prior clinical literature. These are three independent lines of evidence. By contrast, the grouping of INHBB with EMT depends partly on the same TGFβ pathway annotations that motivated its interpretation, so the pathway evidence is not fully independent of the hypothesis being tested.

---

# 6. Limitations and alternative explanations

### 1. Bulk tissue and cell composition
Colorectal tumor tissue contains variable amounts of stroma, immune cells, and normal epithelium. A strong EMT/stromal risk signal could reflect high stromal content rather than tumor-cell EMT. Similarly, the protective mitochondrial/differentiation signal could reflect higher epithelial purity or normal epithelial contamination. This can be addressed using single-cell RNA-seq, spatial transcriptomics, or computational deconvolution and survival models adjusted for stromal fraction.

### 2. Lack of adjustment for stage, treatment, and clinical covariates
The table does not specify whether HRs were adjusted for age, sex, tumor stage, MSI status, or chemotherapy. Since overall survival is strongly influenced by stage and treatment, the reported gene associations may partly reflect associations with disease stage or treatment response rather than independent biological prognostic effects. Multivariable Cox models in independent cohorts are required.

### 3. Potential CMS subtype confounding
Colorectal cancer has well-defined consensus molecular subtypes. CMS2 tumors are enriched for CDX2/differentiation and have better outcomes; CMS4 tumors are enriched for stromal/EMT genes and have worse outcomes. The current gene list may largely reflect the CMS2-versus-CMS4 distinction rather than many independent biological programs. This is biologically interpretable but means that individual genes may be surrogates for a broader subtype.

### 4. Modest effect sizes, correlated genes, and multiple testing
HRs are mostly in the range 0.69–1.43, which is modest for a single biomarker. Many genes within a program are biologically correlated, so the number of independent signals is smaller than the number of significant genes. Some included genes have FDR above 0.05 and should be considered suggestive only. Unknown probes and readthrough/LOC annotations are difficult to interpret functionally.

### 5. Association versus causation and drug-target assumptions
The data cannot establish causality. Even when a risk-associated gene is known to be druggable, this does not mean it is an effective therapeutic target in colorectal cancer. Functional perturbation studies, ideally in patient-derived models, are necessary before any therapeutic claim can be made. In addition, the protective direction of MYB, despite literature describing oncogenic roles in some contexts, illustrates that survival associations may conflict with prior functional expectations; such cases should not be over-interpreted without validation.

---

## Final summary

The data define a biologically coherent survival-associated transcriptome in colorectal cancer: worse OS is associated with TGFβ/activin- and EMT/stroma-related gene expression, while better OS is associated with intestinal differentiation and mitochondrial oxidative metabolism. The strongest individual risk gene is INHBB; the strongest protective module is the CDX1/CDX2 enterocyte differentiation axis together with multiple mitochondrial oxidative phosphorylation genes. However, given the bulk-tissue design, lack of multivariable adjustment, and possible CMS subtype confounding, these conclusions should be treated as supported or exploratory hypotheses requiring independent, cell-type-resolved validation rather than established causal mechanisms.
